PMID- 34409758
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 17
DP  - 2021 Sep
TI  - Clinicopathological and molecular characterizations of pulmonary NUT midline 
      carcinoma.
PG  - 5757-5764
LID - 10.1002/cam4.4096 [doi]
AB  - INTRODUCTION: Pulmonary nuclear protein of the testis (NUT) midline carcinoma 
      (NMC) is a aggressive cancer with t (15, 19) translocation. Here we present the 
      clinicopathological characteristics and molecular genetics alterations of primary 
      pulmonary NMC. METHODS: Fluorescence in situ hybridization (FISH) assay was 
      performed to evaluate NUT translocation. Next generation sequencing (NGS) was 
      performed to investigate genomic landscape. A panel of 289 lung cancer tissues 
      with undifferentiation was retrospectively screened for NUT expression by 
      immunohistochemical (IHC) assay. RESULTS: Overall, 2136 lung cancer samples were 
      reviewed. We consecutively identified 12 cases of primary pulmonary NMC. Computed 
      tomography revealed centrally located bulky lung mass with ipsilateral 
      mediastinal lymph node and pleural involvements. Tumor cells presented diffuse 
      poor differentiation and focal squamous differentiation with positive NUT 
      expression. NUT rearrangement was confirmed by FISH assay. Ten NMC samples were 
      investigated by NGS. The most common alterations identified were P53, PIK3CA, 
      AUTS2, ITIH2, and CDKL5 genes. Pulmonary NMC exhibited increased activity of 
      PI3K/AKT pathway. In the screening study, BRD4-NUT rearrangement was identified 
      in two cases. CONCLUSION: NUT rearrangement remains the gold standard in the 
      diagnosis of pulmonary NMC. PI3K inhibition is a potential targeted therapy for 
      pulmonary NMC.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Xie, Mian
AU  - Xie M
AUID- ORCID: 0000-0002-5013-6673
AD  - Department of Medical Oncology, Guangdong Provincial People's Hospital and 
      Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Fu, Xinge
AU  - Fu X
AD  - Department of Pathology, The First Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou 
      Medical University, Beijing, China.
LA  - eng
GR  - 81672293/National Natural Science Foundation of China/
GR  - 81972178/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210819
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Young Adult
PMC - PMC8419746
OTO - NOTNLM
OT  - NUT midline carcinoma
OT  - lung cancer
OT  - squamous cell carcinoma
COIS- None declared.
EDAT- 2021/08/20 06:00
MHDA- 2022/03/04 06:00
PMCR- 2021/08/19
CRDT- 2021/08/19 07:10
PHST- 2021/05/24 00:00 [revised]
PHST- 2020/11/25 00:00 [received]
PHST- 2021/05/29 00:00 [accepted]
PHST- 2021/08/20 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/08/19 07:10 [entrez]
PHST- 2021/08/19 00:00 [pmc-release]
AID - CAM44096 [pii]
AID - 10.1002/cam4.4096 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Sep;10(17):5757-5764. doi: 10.1002/cam4.4096. Epub 2021 Aug 19.